Curation of the Pancreatic Ductal Adenocarcinoma Subset of the Cancer Genome Atlas Is Essential for Accurate Conclusions about Survival-Related Molecular Mechanisms
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Purpose: Publicly available databases, for example, The Cancer Genome Atlas (TCGA), containing clinical and molecular data from many patients are useful in validating the contribution of particular genes to disease mechanisms and in forming novel hypotheses relating to clinical outcomes. Experimental Design: The impact of key drivers of cancer progression can be assessed by segregating a patient cohort by certain molecular features and constructing survival plots using the associated clinical data. However, conclusions drawn from this straightforward analysis are highly dependent on the quality and source of tissue samples, as demonstrated through the pancreatic ductal adenocarcinoma (PDAC) subset of TCGA. Results: Analyses of the PDAC-TCGA database, which contains mainly resectable cancer samples from patients in stage IIB, reveal a difference from widely known historic median and 5-year survival rates of PDAC. A similar discrepancy was observed in lung, stomach, and liver cancer subsets of TCGA. The whole transcriptome expression patterns of PDAC-TCGA revealed a cluster of samples derived from neuroendocrine tumors, which have a distinctive biology and better disease prognosis than PDAC. Furthermore, PDAC-TCGA contains numerous pseudo-normal samples, as well as those that arose from tumors not classified as PDAC. Conclusions: Inclusion of misclassified samples in the bioinformatic analyses distorts the association of molecular biomarkers with clinical outcomes, altering multiple published conclusions used to support and motivate experimental research. Hence, the stringent scrutiny of type and origin of samples included in the bioinformatic analyses by researchers, databases, and web-tool developers is of crucial importance for generating accurate conclusions. Clin Cancer Res; 24(16); 3813–9. ©2018 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092 · cited 1×
“The Cancer Genome Atlas (TCGA) began cataloging molecular datasets for various cancer types in 2005, and has since grown to include extensive molecular and clinical information for individual cancer patient samples (3).”
BackgroundIntegrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019
A vision for the future of genomics research
Collins, F. S., Green, E. D., Guttmacher, A. E., Guyer, M. S., & on behalf of the US National Human Genome Research Institute (2003) · Nature · doi:10.1038/nature01626 · Cited by 1,752 · cited 1×
“Completion of the Human Genome Project in 2003 (1, 2) allowed for association studies mapping genomic variation, particularly mutations, with disease phenotypes.”
BackgroundThe Human Genome Project: Lessons from Large-Scale Biology
Collins, F. S., Morgan, M., & Patrinos, A. (2003) · Science · doi:10.1126/science.1084564 · Cited by 1,284 · cited 1×
“Completion of the Human Genome Project in 2003 (1, 2) allowed for association studies mapping genomic variation, particularly mutations, with disease phenotypes.”
BackgroundPetersen, G. M. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.09.002 · Cited by 157
Chaffee, K. G., Oberg, A. L., McWilliams, R. R., Majithia, N., Allen, B. A., Kidd, J., Singh, N., Hartman, A.-R., Wenstrup, R. J., & Petersen, G. M. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.85 · Cited by 144
Cited by
Sun, X., He, X., Zhang, Y., Hosaka, K., Andersson, P., Wu, J., Wu, J., Jing, X., Du, Q., Hui, X., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-322744 · Cited by 233
Zhu, T., Liu, J., Beck, S., Pan, S., Capper, D., Lechner, M., Thirlwell, C., Breeze, C. E., & Teschendorff, A. E. (2022) · Nature Methods · doi:10.1038/s41592-022-01412-7 · Cited by 103
Gu, Y., Ji, Y., Jiang, H., & Qiu, G. (2020) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2020.0078 · Cited by 28
“We used the corresponding survival data from TCGA dataset (Peran et al. , 2018; Nicolle et al. , 2019) to analyze (Peran et al. , 2018; Nicolle et al. , 2019) and explore the association between TP53 , P16, SMAD4 , and KRAS expression and PADC patients’ clinical outcome (Supplementary Fig.”
Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels
Panebianco, C., Trivieri, N., Villani, A., Terracciano, F., Latiano, T. P., Potenza, A., Perri, F., Binda, E., & Pazienza, V. (2021) · Biomolecules · doi:10.3390/biom11050639 · Cited by 26
“[37], samples of various origin and (pseudo)- normal samples were excluded.”
Background
Metadata
- Authors
- Peran, I., Madhavan, S., Byers, S. W., & McCoy, M. D.
- Venue
- Clinical Cancer Research
- Published
- 2018-08-14
- Volume
- 24
- Issue
- 16
- Pages
- 3813-3819
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2801452528
- Cited by
- 95
- References
- 6
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Curation of the Pancreatic Ductal Adenocarcinoma Subset of the Cancer Genome Atlas Is Essential for Accurate Conclusions about Survival-Related Molecular Mechanisms. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-0290
- The paper
- Peran, I., Madhavan, S., Byers, S. W., & McCoy, M. D. (2018). Curation of the Pancreatic Ductal Adenocarcinoma Subset of the Cancer Genome Atlas Is Essential for Accurate Conclusions about Survival-Related Molecular Mechanisms. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-0290
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.